Shizuoka Prefecture and Boehringer Ingelheim Japan Sign Partnership Agreement to Combat Chronic Kidney Disease
Shizuoka Prefecture has signed a partnership agreement with the pharmaceutical company Boehringer Ingelheim Japan to strengthen measures against chronic kidney disease (CKD). This agreement aims to protect the health of prefecture residents and reduce the future burden of medical expenses.
Chronic kidney disease often progresses without noticeable symptoms, and if left untreated, it carries the risk of requiring dialysis. Through this agreement, both parties plan to jointly conduct awareness activities to help residents detect the disease early and receive appropriate treatment.
Specifically, the plan is to work with local medical institutions to establish check-up systems during health screenings, and to disseminate accurate knowledge about the disease through seminars and information provided to citizens. Efforts will also be focused on creating an environment where patients can seek consultation with peace of mind.
Boehringer Ingelheim Japan will leverage its accumulated professional expertise and pharmaceutical information to support initiatives aimed at extending the healthy life expectancy of Shizuoka Prefecture residents. Through this public-private partnership, the prefecture aims to build a community where more people can live healthy lives.
This initiative is attracting attention as a model case for kidney disease countermeasures, which is a challenge faced nationwide. Many stakeholders are looking forward to seeing how specific activities will be carried out within Shizuoka Prefecture in the future.